|
|
|
|
|
|
|
|
|
|
|
05.09.25 - 13:30
|
Steel cut for Yara Eyde – world′s first ammonia-powered container ship (Cision)
|
|
|
This milestone represents a major step forward in maritime decarbonization, driven by the joint leadership of Yara Clean Ammonia, Yara International, CMB.TECH and North Sea Container Line.
[Steel cutting ceremony]
Yara Clean Ammonia, the world's largest shipper and trader of ammonia, today celebrated the Steel Cutting Ceremony for Yara Eyde, the world's first renewable ammonia-powered container ship. This milestone marks the official start of construction for a vessel that will transform short-sea shipping and demonstrate the potential of ammonia as a low-emission fuel.
Set to...
|
|
|
|
|
|
|
04.09.25 - 17:33
|
Biocodex Invests up to €30 Million in MRM Health, a Belgian Microbiome Therapy Innovator (Business Wire)
|
|
|
GENTILLY, France--(BUSINESS WIRE)--Biocodex, a French family-owned pharmaceutical pioneer in microbiota research for over 70 years, announces a strategic equity investment of €11 million in MRM Health, a Belgian clinical-stage biotech developing innovative microbiome-based therapeutics for inflammatory diseases and immune-oncology. The total partnership could reach approximately €30 million, reflecting Biocodex's long-term commitment to advancing new therapeutic approaches.
MRM Health's €55 million Series B round was led by Biocodex, with strong participation from ATHOS, new investor BNP Paribas Fortis Private Equity, and existing investors SFPIM (Belgium's sovereign wealth fund), Ackermans & van Haaren (AvH), OMX Ventures Europe (OMX), and Qbic II.
MRM Health is developing innovative treatments based on the human microbiome to address major diseases such as Inflammatory Bowel Diseases, autoimmune disorders, and certain cancers. Its lead asset, the flagship molecule MH002, has completed successfu...
|
|
|
|
|
|
|
|
|
04.09.25 - 07:06
|
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline (Business Wire)
|
|
|
Funding to support Phase 2b trial with MRM Health's lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Strategic partnership with Biocodex in biotherapeutics development and manufacturing adds significant non-dilutive funding in addition to the Series B financing
Investment fuels expansion of proprietary CORAL® platform and pipeline
GHENT, Belgium--(BUSINESS WIRE)--#Parkinson--MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round.
The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB.
Validation of Leadership Position in Microbiome-Based Therapeutics
...
|
|
|
|
|
|
|
02.09.25 - 21:36
|
Erdogan Slams US For Blocking Palestinian Leaders At UN; Belgium Sanctions Israel (ZeroHedge)
|
|
|
Erdogan Slams US For Blocking Palestinian Leaders At UN; Belgium Sanctions Israel
Turkish President Recep Tayyip Erdogan is fuming after the Trump administration blocked Palestinian Authority (PA) leaders from attending the upcoming United Nations General Assembly meeting in New York scheduled for later this month.
PA leader Mahmoud Abbas is not being issued a visa to enter US soil (along with his delegation), as retribution for his leading the charge in support of a Palestinian state, and for waging a 'lawfare campaign' against Prime Minister Netanyahu and other Israeli officials. Erdogan said this only plays into Israel's hands, which is busy conducting "massacres" and "cruelty" in Gaza.
Source: Xinhua
The move "does not fit the United Nations' raison d'etre," Erdogan told reporters on a flight after leaving China, where he attended the SCO Tianjin Summit 2025. "The decision needs to be urgently revised. The United Nations General Assembly exists for...
|
|
|
|
|
|
|
|
|
|
|
02.09.25 - 08:57
|
Llama Group SA: Decisions of the Extraordinary General Meeting of August 28, 2025 (Business Wire)
|
|
|
BRUSSELS--(BUSINESS WIRE)--Regulatory News:
Llama Group SA (Euronext Growth Paris & Brussels: ALLAM) announces that its Extraordinary General Meeting was held on Thursday, August 28, 2025.
The shareholders approved the following resolutions:
1. Issuance of subscription rights
In the context of the capital increase of €1,000,000 carried out on July 10, 2025 through the issuance of 1,666,668 new shares at a subscription price of €0.60 per share, the Meeting confirmed the issuance of 1,166,668 subscription rights to the investors who participated in this transaction.
Each right grants the possibility to subscribe, at a later stage, to one new ordinary share at an exercise price of €0.80. The corresponding capital increases will be carried out in proportion to the number of subscription rights exercised and will result in the issuance of new shares.
2. Approval of the Loan Agreement with Maxximum SA
The Meeting approved the Loan Agreement entered into on April 25, 2025 between Llama Group and Maxximum S...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
